Introduction
In primary hyperparathyroidism (PHPT), the proper identification of a hyperfunctioning parathyroid gland is often a concerted series of investigations using biochemical, radiological, surgical, and histological approaches. For most instances, a single adenoma is usually identified through laboratory analyses suggesting elevated serum levels of calcium and/or parathyroid hormone (PTH), and preoperative localization techniques may vary among institutions, but most often include neck ultrasound and/or Technetium (99mTc) sestamibi scintigraphy [
1,
2]. If the adenoma is pinpointed preoperatively, a focused parathyroidectomy is the preferred strategy as opposed to a more time-consuming bilateral neck exploration of all four glands. Upon histological evaluation, the pathologist relies on the architecture of the excised gland as well as the proportion of stromal fat. A normal gland usually is composed by at least 25% fat, but the proportion might vary with patient age and body habitus [
3‐
5]. Also, the sheer glandular mass is brought into consideration, in which normal glands regularly exhibit weights below 60 mg [
6]. Information regarding intraoperative PTH measurements and/or postoperative biochemistry may also constitute useful information, but the picture is complicated by the frequent occurrence of multiglandular disease in PHPT.
Parathyroid lipoadenomas (PLAs) constitute a rare manifestation of PHPT, and few cases have been described in the scientific literature [
4,
7‐
51]. The phenotype was firstly denoted as “parathyroid hamartoma,” but the term “lipoadenoma” gained ground and has since emerged as the most appropriate connotation. The histology bears some similarities to that of a normal parathyroid gland, with a generous proportion of stromal fat and small, labyrinth-like nests of parathyroid cells, mostly chief cells arranged in cords or acini [
5]. This makes the distinction between a normal gland and PLA equivocal, and hence some authors propose that the PLA diagnosis should be exclusively used for single adenomas with a clear-cut, postoperative withdrawal of biochemical signs of PHPT [
4]. However, this stringent definition could potentially exclude cases in which PLAs develop synchronously with a conventional adenoma, which probably is a not entirely uncommon feature given the proportion of cases of PLAs than do not resolve biochemically after surgical exploration [
46].
Other histological features of PLAs include reports of a myxoid, stromal appearance, and, occasionally, the PLA may exhibit admixtures of thymic tissue [
8,
9,
11,
17,
28,
33]. A single case has also been reported to display brown fat tissue rather than conventional adipose tissue [
51].
From a preoperative perspective, the high adipose tissue content also makes PLAs harder to detect by preoperative imaging techniques compared to conventional adenomas, putting even more emphasis on the clinical enigmas of this tumor subtype [
26,
29,
38,
50]. This is not least important, given the fact that subsets of PLAs arise in ectopic locations [
41,
42]. Moreover, surgical pathologists who are consulted per-operatively for frozen section diagnosis during parathyroid and thyroid surgery need to be aware of this tumor entity as well. This is especially important when engaged in frozen section assessment of biopsies of parathyroid glands, as the sheer ratio of parathyroid vs stromal fat cells is not entirely reliable to rule out a hyperfunctioning gland [
46].
In this study, we sought to characterize the frequency of PLA in a large, institutional series of parathyroid tumors diagnosed in our endocrine pathology tertiary center at Karolinska University Hospital in Stockholm, Sweden. We hereby present one of the largest case series collected and discuss correlations to clinical characteristics of potential interest for future studies.
Materials and Methods
Study Cohort and Case Review
We explored the institutional pathology database at Karolinska University Hospital using a general search function using taxonomy based on the Systematized Nomenclature of Medicine (SNOMED) algorithm. The nomenclature chosen was T97*** for parathyroid and M83240 for lipoadenoma. The search was limited from January 1, 1992, to January 31, 2020, as pathology reports prior to 1992 were not incorporated digitally and hence no SNOMED registrations for these cases exist. External consultation cases were excluded to avoid referral bias. All cases retrieved were subsequently retrieved from the pathology repositories and reviewed by conventional light microscopy by two of the authors (CCJ, AH). For this case series, we used a definition in which parathyroid lipoadenoma was denoted as an enlarged parathyroid gland demonstrating a definite increase in parathyroid acinar tissue and > 50% fat on histologic examination excised from a patient exhibiting primary hyperparathyroidism. However, it should be noted that various definitions are used across the scientific literature, and previous reports of this tumor entity reported from a wide variety of institutions only occasionally defined the histological criteria. Moreover, the term “lipohyperplasia” is sometimes used in the literature and usually refers to the synchronous development of several fat-rich enlarged parathyroid glands with our without the postoperative abolishment of hypercalcemia [
35,
52]. In our study, patients displaying two or more PLAs synchronously were defined as exhibiting “lipohyperplasia.”
Clinical Characteristics and Patient Follow-Up
Patients’ medical charts were reviewed thoroughly, and clinical parameters of potential interest were noted for all cases included. Parameters included sex, disease presentation, radiology, complications related to PHPT, tumor weight, co-morbidity, medications, smoking habits, body mass index, age at surgery, surgical complications, length of hospital stay, pre- and postoperative biochemistry, and follow-up time. Outcomes measured were either resolution of PHPT or persistent/recurrent hypercalcemia. Mortality and cause of death was also recorded.
Institutional Control Cohorts
Data from a clinical control cohort of 110 conventional parathyroid adenomas operated at the Karolinska University Hospital between 2014 and 2018 was used as reference for clinical comparisons with our study. The cohort comprises consecutive cases operated for PHPT at our institution after signed consent. Detailed inclusion and exclusion criteria are available through
ClinicalTrials.gov (NCT 02227264). The cohort has been previously published and derives from a registry with comprehensive and biochemical workup, of which we extracted information regarding patient gender, age at surgery, tumor weight, and body mass index (BMI) as well as information regarding persistent or recurrent hyperparathyroidism following surgery [
53].
Additionally, to verify that cases annotated as conventional adenomas by SNOMED coding in our institutional series in fact were adenomas with a low adipose tissue proportion and not missed cases of lipoadenomas, we retrieved a total of 200 parathyroid lesions SNOMED coded as adenomas (SNOMED nomenclature M81400) from our tissue archives and reviewed the histology. We refer to this collection as the “histological control group.” These cases were randomly selected from a filtered list of parathyroid adenomas operated at Karolinska between 2016 and 2020, and subsequently matched with the study cohort regarding age at surgery. We then classified the adipose tissue content of each adenoma semi-quantitatively using pre-defined ranges (< 5%, 5%, 10%, 15%, 20%, 25%, or > 25% fat).
Statistical Analyses
The Mann–Whitney U, Kruskal–Wallis, and Fisher’s exact tests were used to compare the tumor groups for differences in clinicopathological variables. P values < 0.05 were considered significant. All statistical calculations were performed in SPSS Statistics 26 software (IBM, Armonk, North Castle, New York, USA).
Discussion
Although the main bulk of parathyroid tumors is routinely diagnosed by conventional histology, specific subgroups demand increased attention. This is particularly true for parathyroid carcinoma and the borderline group “atypical adenoma,” of which auxiliary immunohistochemical and genetic analyses have facilitated the detection of cases exhibiting malignant potential [
54,
55]. Another troubling aspect of diagnosing parathyroid tumors revolves around the proper identification of PLAs and separating them from normal parathyroid glands, not least in an intraoperative diagnostic setting using frozen sections. As the amount of reported PLAs across the scientific literature is exceedingly low (< 100 cases), detailed descriptions of large case series with coupling to clinical parameters are warranted.
In our material, we confirm earlier observations that PLA patients exhibit classical features of PHPT, with modest symptoms related to hypercalcemia [
4,
46]. Patients were largely postmenopausal females exhibiting single adenomas with the postoperative resolution of hypercalcemia, with similar age, tumor weight, and BMI as patients with conventional adenomas. No PLA case in our series displayed evidence of atypia or features associated to parathyroid carcinoma. We furthermore acknowledge the rarity of these lesions, with a prevalence of 0.20% in our material. Interestingly, no PLA case was detected in our databases prior to 2005, although the search was conducted in material from 1992 and onwards. The reason for this observation could be previous inadequate SNOMED coding of rare variants, and/or a simple question of sample volumes, as parathyroid surgery volumes rose significantly around 2005 following a departmental concentration of all endocrine surgery in Stockholm.
Histologically, a single case (case 7) was built up by an abundance of brown adipocytes with an associated cord-like distribution of parathyroid chief cells. This patient was a 61-year-old male displaying clinical signs of depression as well as elevated serum calcium and plasma PTH levels. To our knowledge, this is the second description of such a brown fat PLA available in the literature [
51].
No clear-cut association between the development of PLAs and patient BMI was noted, although the restricted number of patients in this case series is a clear limitation to these observations. Nevertheless, the PLA group exhibited a median BMI of 25.9 kg/m
2 (range 20.7–49.5). Consulting previous BMI results of unselected Swedish PHPT patients (
n = 150), a median BMI value of 26 kg/m
2 has been reported, which is in line with data from our PLA cohort [
56]. Further comparisons with a clinical control cohort of 110 cases yielded no significant correlation either, and hence an eventual association to body composition would have to be sought in a larger material, preferably through a comprehensive meta-analysis.
Regarding arterial hypertension, the vast majority of PLA and equivocal PLA patients were hypertensive and received anti-hypertensive drugs. In the scientific literature, PHPT is tightly coupled to hypertension, and 35–55% of PHPT patients have been reported to suffer from this condition [
57]. Although the results from our limited PLA cohort might be a reflection of sampling bias, the potential association could be of clinical importance worthy of attention in subsequent studies of hypertension and hypertensive medications in the PHPT population.
Two PLA patients (two females, 53- and 75-year-old) in our series exhibited borderline tumors in terms of histological presentation and were therefore separated for most analyses. Intriguingly, one of these patients exhibited a positive family history, with two first-degree relatives with PHPT. Unfortunately, these family members were lost to follow-up, and no investigations could be performed as to whether their tumors also were lipomatous. A single case of “lipohyperplasia” was also noted. This male patient was 50 years old at surgery and was excluded from the PLA group based on the findings of two enlarged glands. He is still hypercalcemic and asymptomatic, but followed biochemically. He exhibited a BMI of 25.1 kg/m2 at surgery and had no family history indicative of PHPT or additional medical history, except for successful treatment of a deep vein thrombosis.
In this study, we chose to include the eight parathyroid lesions from seven patients that were originally suspected to constitute lipoadenomas, but failed inclusion after histological review. We appointed these cases as “fat-rich pathological parathyroid glands” and found that they were significantly smaller than the PLAs of this cohort. These parathyroid glands were all enlarged but exhibited a stromal fat content of < 50%, but above 25%. Even though the stromal fat proportion was higher than usually seen in conventional adenomas, the enlarged gland made the pathologist reluctant of diagnosing these glands as normal—which was probably correct given the resolution of hypercalcemia in the majority of patients. To support this, conventional adenomas at our institution were consistently fat-depleted when reviewed histologically, and not a single case of the 200 tumors re-evaluated displayed an adipose tissue proportion of > 25%. Interestingly, recent findings from Australia suggest the occurrence of a histological subgroup which the authors entitled “large normal” parathyroid glands (LNPs)—defined by an enlarged parathyroid gland with near-normal histology followed by the postoperative resolution of hypercalcemia [
58]. The prevalence of LNP in that specific study was 2%, compared to the PLA prevalence of < 0.5% in our series—making the former an entity of certain clinical impact, as several cases are expected annually in parathyroid high-volume centers. It seems as though our group of so-called fat-rich pathological parathyroid glands bear many similarities with the definition of LNPs, and might indicate a subgroup within the PHPT family of disease entities.
Interestingly, three out of seven patients with a fat-rich pathological parathyroid gland in our study did not resolve biochemically; one case resolved 18 months postoperatively after the excision of a conventional adenoma, and the remaining two are still not cured. Indeed, the study cohort displayed significantly worse clinical outcome in terms of resolution of hyperparathyroidism compared to the clinical control cohort. This highlights the intricacy of these patients from a clinical perspective and might signify that several patients with fat-rich parathyroid lesions exhibit clinically elusive multiglandular disease.
In all, it seems safe to conclude that a proportion of pathological parathyroid lesions in patients with PHPT is hard to detect histologically by means of tumoral weight and stromal fat content only. Hence, more emphasis on a holistic process of diagnosing these lesions seems appropriate, in which histology and postoperative, biochemical workup is merged. Future studies might help dissect whether there is a continuous spectrum of disease development, from a normal gland, via LNPs to PLAs and/or conventional adenomas, or if the different entities are branched with associated, underlying exogenous factors and/or genetic aberrancies governing the development of each unique group. Indeed, future meta-analyses of PLAs might bring new light to the possible etiologies of these lesions, including the observed association with hypertension described here.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.